• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于图像的转移性鼻咽癌 TNM 分期系统 M1 亚类的多层次细分。

Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.

机构信息

From the Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou 510060, People's Republic of China (L.S., W.L., Q.Z., F.S., W.S., P.W.); State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China (L.S., C.C., Y.Z., M.W., Y.X., P.W.); Department of Radiation Oncology, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, People's Republic of China (S.W., Q.Z., C.C., Y.X.); Department of Radiation Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, People's Republic of China (G.X.); Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Chengdu,, People's Republic of China (C.P.); and Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, People's Republic of China (Y.Z., M.W., W.S.).

出版信息

Radiology. 2016 Sep;280(3):805-14. doi: 10.1148/radiol.2016151344. Epub 2016 Mar 29.

DOI:10.1148/radiol.2016151344
PMID:27023116
Abstract

Purpose To establish an image-based M1 category subdivision system for personalized prognosis prediction and treatment planning in patients with metastatic nasopharyngeal carcinoma (NPC). Materials and Methods A total of 1172 patients with metachronous metastasic NPC were retrospectively enrolled (the dataset is from Sun Yat-sen University Cancer Center for derivation, and the combined datasets are from Guangzhou Medical University Cancer Center and the Fifth Affiliated Hospital of Sun Yat-sen University for validation). The Ethics Committee of the three centers approved this study. A general subdivision system of the M1 category was established on the basis of the most influential metastatic features for overall survival (OS). The following multilevel subdivision system for precise subdivision of the M1 category was designed: M [number of locations]-Location [number of lesions], with B indicating bone, L indicating the lung, H indicating the liver, and N indicating a node. The correlation of the M1 subdivisions with OS was determined with Cox regression. The best treatment response was assessed with Response Evaluation Criteria in Solid Tumors 1.1 guidelines and modified Response Evaluation Criteria in Solid Tumors criteria. Results Multivariate analysis in the derivation cohort showed that the number of metastatic lesions (multiple or single), the number of metastatic locations (multiple or single), liver involvement, and bone involvement were independent prognostic factors for OS. In general, subdividing the cohort by the number of metastatic lesions and the number of metastatic locations resulted in three subcategories of differential OS: M1a, a single lesion in a single organ or location; M1b, multiple lesions in a single organ or location; and M1c, metastases in multiple locations (for M1b vs M1a, hazard ratio [HR] = 2.28, 95% confidence interval [CI]: 1.71, 3.05; for M1c vs M1a, HR = 3.65, 95% CI: 2.75, 4.85); these subdivisions were externally validated. The multilevel subdivision system could be further used to discriminate among subgroups of differential OS under the M1b subcategory. Findings from analysis of multilevel subgroups suggested that patients with a single metastatic lesion (M1-B1, M1-L1, M1-H1, M1-N1) or two lesions in the liver only (M1-H2) had high rates of complete response (CR) or complete surgical resection (CSR) and 3-year OS after treatment (CR plus CSR rates >30%, and 3-year OS rates >50%); there were high 3-year OS rates (>50%) in patients with stage M1-B2, M1-L2, or M1-H3 disease but relatively low rates of CR or CSR. Conclusion Use of the multilevel M1 subdivision system in patients with NPC could facilitate more precise prognosis prediction and better identification of patients who will respond well to treatment than the conventional subdivision strategy. (©) RSNA, 2016 Online supplemental material is available for this article.

摘要

目的 建立基于影像的转移性鼻咽癌(NPC)患者 M1 亚类细分系统,以进行个性化预后预测和治疗计划。

材料与方法 回顾性纳入 1172 例 NPC 患者(数据集来源于中山大学肿瘤防治中心,联合数据集来源于广州医科大学肿瘤医院和中山大学第五附属医院)。三个中心的伦理委员会批准了这项研究。在影响总生存(OS)的最具影响力的转移特征的基础上,建立了 M1 亚类的一般细分系统。设计了以下 M1 类的精确细分的多层次细分系统:M[位置数量]-Location[病变数量],其中 B 表示骨,L 表示肺,H 表示肝,N 表示淋巴结。使用 Cox 回归确定 M1 亚类与 OS 的相关性。使用实体瘤反应评价标准 1.1 指南和改良实体瘤反应评价标准评估最佳治疗反应。

结果 在推导队列中的多变量分析显示,转移灶数量(多个或单个)、转移灶部位数量(多个或单个)、肝受累和骨受累是 OS 的独立预后因素。一般来说,根据转移灶数量和转移灶部位数量对队列进行细分,会导致 OS 存在三个不同的亚类:M1a,单个器官或部位的单个病变;M1b,单个器官或部位的多个病变;M1c,多个部位转移(M1b 与 M1a 相比,危险比[HR] = 2.28,95%置信区间[CI]:1.71,3.05;M1c 与 M1a 相比,HR = 3.65,95%CI:2.75,4.85);这些亚类在外部得到验证。多层次细分系统可进一步用于区分 M1b 亚类中具有不同 OS 的亚组。多水平亚组分析的结果表明,治疗后具有单个转移灶(M1-B1、M1-L1、M1-H1、M1-N1)或仅肝内两个转移灶(M1-H2)的患者具有高完全缓解(CR)或完全手术切除(CSR)率和 3 年 OS(CR+CSR 率>30%,3 年 OS 率>50%);M1-B2、M1-L2 或 M1-H3 疾病患者的 3 年 OS 率较高(>50%),但 CR 或 CSR 率相对较低。

结论 与常规细分策略相比,在 NPC 患者中使用多层次 M1 亚类细分系统可更精确地预测预后,并更好地识别对治疗反应良好的患者。

相似文献

1
Image-based Multilevel Subdivision of M1 Category in TNM Staging System for Metastatic Nasopharyngeal Carcinoma.基于图像的转移性鼻咽癌 TNM 分期系统 M1 亚类的多层次细分。
Radiology. 2016 Sep;280(3):805-14. doi: 10.1148/radiol.2016151344. Epub 2016 Mar 29.
2
Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system.鼻咽癌伴同步转移的M分类细分:是时候扩展M分类系统了。
Chin J Cancer. 2015 Aug 12;34(10):450-8. doi: 10.1186/s40880-015-0031-9.
3
M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma.鼻咽癌单纯骨转移患者的M1期细分及治疗结果
Oncologist. 2015 Mar;20(3):291-8. doi: 10.1634/theoncologist.2014-0206. Epub 2015 Feb 6.
4
Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.基于决策树分类的 M1 期鼻咽癌亚分期的建立:一项多中心回顾性研究。
Oral Oncol. 2024 Jun;153:106834. doi: 10.1016/j.oraloncology.2024.106834. Epub 2024 May 7.
5
Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment.初发性转移性鼻咽癌M1期细分的建立与验证,以更好地预测预后并指导治疗。
Eur J Cancer. 2017 May;77:117-126. doi: 10.1016/j.ejca.2017.02.029. Epub 2017 Apr 7.
6
Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.非流行地区与同步转移性鼻咽癌患者生存相关的转移特征。
Oral Oncol. 2021 Apr;115:105200. doi: 10.1016/j.oraloncology.2021.105200. Epub 2021 Feb 19.
7
Anatomic prognostic factors and their potential roles in refining M1 classification for de novo metastatic nasopharyngeal carcinoma.初诊转移性鼻咽癌的解剖预后因素及其在 M1 分类中的潜在作用。
Cancer Med. 2023 Dec;12(24):22091-22102. doi: 10.1002/cam4.6816. Epub 2023 Dec 11.
8
Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery.将初发转移性乳腺癌 M1 分期细分,以更好地预测预后和原发肿瘤手术的反应。
J Natl Compr Canc Netw. 2019 Dec;17(12):1521-1528. doi: 10.6004/jnccn.2019.7332.
9
Oligometastases in AJCC stage IVc nasopharyngeal carcinoma: A subset with better overall survival.美国癌症联合委员会(AJCC)IVc期鼻咽癌中的寡转移:总生存期较好的一个亚组。
Head Neck. 2016 Aug;38(8):1152-7. doi: 10.1002/hed.24345. Epub 2016 May 24.
10
A nomogram for predicting survival of nasopharyngeal carcinoma patients with metachronous metastasis.预测鼻咽癌异时转移患者生存情况的列线图。
Medicine (Baltimore). 2016 Jul;95(27):e4026. doi: 10.1097/MD.0000000000004026.

引用本文的文献

1
Whether Primary Bone-Only Oligometastatic Nasopharyngeal Carcinoma Patients Benefit From Radiotherapy to the Bones on the Basis of Palliative Chemotherapy Plus Locoregional Radiotherapy?-A Large-Cohort Retrospective Study.基于姑息性化疗联合局部区域放疗,单纯骨寡转移的鼻咽癌患者是否从骨放疗中获益?一项大型回顾性研究。
Cancer Med. 2024 Nov;13(21):e70315. doi: 10.1002/cam4.70315.
2
Enhancing efficacy and reducing toxicity: Therapeutic optimization in locoregionally advanced nasopharyngeal carcinoma.提高疗效,降低毒性:局部晚期鼻咽癌的治疗优化。
Cell Rep Med. 2024 Jun 18;5(6):101594. doi: 10.1016/j.xcrm.2024.101594. Epub 2024 Jun 5.
3
Comprehensive integrated analysis of MR and DCE-MR radiomics models for prognostic prediction in nasopharyngeal carcinoma.
用于鼻咽癌预后预测的磁共振成像(MR)和动态对比增强磁共振成像(DCE-MR)影像组学模型的综合分析
Vis Comput Ind Biomed Art. 2023 Dec 1;6(1):23. doi: 10.1186/s42492-023-00149-0.
4
Oligometastatic Head and Neck Cancer: Challenges and Perspectives.寡转移头颈癌:挑战与展望
Cancers (Basel). 2022 Aug 11;14(16):3894. doi: 10.3390/cancers14163894.
5
M1 stage subdivisions based on F-FDG PET-CT parameters to identify locoregional radiotherapy for metastatic nasopharyngeal carcinoma.基于F-FDG PET-CT参数的M1期细分,以确定转移性鼻咽癌的局部区域放射治疗。
Ther Adv Med Oncol. 2022 Aug 12;14:17588359221118785. doi: 10.1177/17588359221118785. eCollection 2022.
6
An Exploratory Study of Refining TNM-8 M1 Categories and Prognostic Subgroups Using Plasma EBV DNA for Previously Untreated De Novo Metastatic Nasopharyngeal Carcinoma.利用血浆EBV DNA对初治的新发转移性鼻咽癌细化TNM-8 M1分类和预后亚组的探索性研究
Cancers (Basel). 2022 Apr 11;14(8):1923. doi: 10.3390/cancers14081923.
7
Subphrenic Lymph Node Metastasis Predicts Poorer Prognosis for Nasopharyngeal Carcinoma Patients With Metachronous Metastasis.膈下淋巴结转移提示异时性转移鼻咽癌患者预后较差。
Front Oncol. 2021 Oct 1;11:726179. doi: 10.3389/fonc.2021.726179. eCollection 2021.
8
Prognostic Factors for Overall Survival in Nasopharyngeal Cancer and Implication for TNM Staging by UICC: A Systematic Review of the Literature.鼻咽癌总生存的预后因素及国际抗癌联盟(UICC)TNM分期的意义:文献系统综述
Front Oncol. 2021 Sep 2;11:703995. doi: 10.3389/fonc.2021.703995. eCollection 2021.
9
Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.地方性鼻咽癌治疗后液体活检监测:整合循环游离 Epstein-Barr 病毒 DNA 的一种具有成本效益的策略。
BMC Med. 2021 Aug 26;19(1):193. doi: 10.1186/s12916-021-02076-4.
10
Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma - 2020 Guangzhou Recommendations.《肝细胞癌微创与多学科综合治疗共识——2020广州推荐意见》
Front Oncol. 2021 Jul 2;11:621834. doi: 10.3389/fonc.2021.621834. eCollection 2021.